Search results
Mar 16, 2021 · In the J&J trial, the placebo group had 16 hospitalizations and seven deaths from COVID-19, whereas the vaccine group had none, which means the vaccine provided 100 percent efficacy against hospitalizations and deaths.
Jan 6, 2022 · The Johnson & Johnson COVID-19 vaccine demonstrated a profile that showed durability of effectiveness up to 6 months for hospitalizations and ICU admissions across the study period, with a modest increase in breakthrough infections starting in month 4.
Feb 9, 2022 · Vaccine efficacy was 70.2% (95% CI, 35.3 to 87.6) against moderate to severe–critical Covid-19 caused by the B.1.1.7 (alpha) variant; 69.0% (95% CI, 59.1 to 76.8) against moderate to...
Sep 21, 2021 · 74 percent efficacy in the U.S. against severe/critical COVID-19 (CI, 39%-91%); 89 percent against hospitalization (CI, 24%-100%); 83 percent against COVID-19-related death (CI, 41%-97%). Booster shot at two months provided 94 percent protection against COVID-19 in the U.S.
Apr 19, 2024 · Efficacy: Overall, 66.1% efficacy in preventing moderate to severe COVID-19 in adults 28 days or more after vaccination, but efficacy was higher in the U.S. population (72% efficacy...
Mar 5, 2021 · Clinical research found it to be 85% effective in preventing severe disease four weeks after vaccination, and it has demonstrated promising indications of protection against a couple of...
Johnson & Johnson is testing a coronavirus vaccine known as JNJ-78436735 or Ad26.COV2.S. Clinical trials showed that a single dose of the vaccine had an efficacy rate of 72 percent in the...
